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Abstract
Muscle wasting, characterized by the loss of protein mass in myofibers, is in most cases largely due
to the activation of intracellular protein degradation by the ubiquitin proteasome system (UPS).
During the last decade, mechanisms contributing to this activation have been unraveled and key
mediators of this process identified. Even though much remains to be understood, the available
information already suggests screens for new compounds inhibiting these mechanisms and
highlights the potential for pharmaceutical drugs able to treat muscle wasting when it becomes
deleterious. This review presents an overview of the main pathways contributing to UPS activation
in muscle and describes the present state of efforts made to develop new strategies aimed at
blocking or slowing muscle wasting.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Roles of the UPS in muscle wasting
Skeletal muscle wasting, or atrophy, is characterized by a
reduction in muscle mass due to an imbalance between
protein synthesis and degradation, resulting in a loss of
net protein content in the myofibers (see reviews cited in
[1] for more information). Even though there is clear evi-
dence that a reduction in protein synthesis participates in
this process, there is now a large body of experiments
showing that a central mechanism in muscle wasting is
increased intracellular proteolysis, due in particular (but
not exclusively [2]) to the activation of the ubiquitin pro-
teasome system (UPS) [3,4].
Muscle wasting occurs in a variety of physiological or
pathological circumstances, including inactivity or muscle
disuse, fasting and many diseases such as cancer, renal
failure or trauma [5]. As skeletal muscle is the major pro-
tein reservoir of the body, muscle wasting has beneficial
effects in its initial stage since it provides the organism
with an ample pool of free amino acids that can be reused
for energy production or protein synthesis in vital organs
[6]. However, in a variety of pathologies such as cancer,
sepsis and diabetes, this catabolic state is maintained over
a long period of time and can become life-threatening;
this condition is often referred to as cachexia [7].
The aim of this review is to provide an overview on the
role of the UPS in muscle wasting. For the sake of space,
only the mechanisms presently thought to be common to
most types of muscle wasting are described, and the reader
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is invited to refer to numerous recent reviews for more
detailed information on specific topics [1,5,6,8-11]. It
should be noted that most of the results described in this
review were obtained with animal models of severe mus-
cle wasting. Therefore, extrapolation to humans of the
mechanisms presented below should be treated with cau-
tion.
UPS components involved in muscle wasting
Initial studies, mostly performed using muscles isolated
from animals subjected to induced muscle wasting, led to
the conclusion in the early 1990s that increased ATP-
dependent proteolysis accounted for a large part of muscle
protein loss in several muscle wasting models [12]. After
the subsequent recognition that the UPS (initially discov-
ered and dissected in rabbit reticulocyte lysate [13-15])
was responsible for ATP-dependent proteolysis in mam-
malian cells [16], and the demonstration that its general
inhibition by proteasome inhibitors reduces the acceler-
ated proteolysis in atrophying muscles [17], several
groups turned to the analysis of expression of individual
UPS components in different experimental models of
muscle wasting (see Table 1).
In general, the UPS functions in two distinct steps to
degrade intracellular proteins. First, the substrate protein
is labeled by covalent linkage of polyubiquitin (polyUb)
chain(s) to one or several lysine residue(s) by the action
of an enzymatic cascade involving three types of factors,
referred to as E1, E2s and E3s [18]. In this reaction, the E3s
act as substrate recognition factors and are thus the main
determinants of the specificity of the UPS [19]. Conse-
quently, their number is very high, with a rough estima-
tion of several hundred E3s present in the genome,
depending on the organism [20]. The second step in pro-
tein degradation by the UPS is the degradation of the
polyubiquitylated substrate by the 26S proteasome, a
large compartmentalized protease comprising the 20S
proteasome, which contains the proteolytic active sites in
its internal catalytic chamber, and the 19S regulatory com-
plex, which is essential for degradation of ubiquitylated
proteins [21,22].
A common theme in most models of muscle wasting is a
significant increase at the mRNA level of many compo-
nents of the UPS. These include ubiquitin (Ub), E2s, pro-
teasome subunits (20S and 19S), deubiquitylating
enzymes and certain E3s [6,8,23-25]. The accepted inter-
pretation is that this upregulation of UPS mRNAs partici-
Table 1: Main conditions used to induce muscle wasting in animals (mice and rats) and the variation of key components involved in 
UPS activation. Please note that the models in this table were generated only for the experiments: muscle wasting was induced in 
normal animals by various treatments and the molecular mechanisms subsequently analyzed.
Main models of 
muscle wasting
Variation of key components involved in UPS activation
UPS mRNAs N-end rule 
pathway
NFκB activity MuRF-1 MAFbx Selected 
reference
Cancer cachexia [84,100]
Sepsis [101,102]
Hindlimb 
suspension
[89,103]
Denervation ? [17,31,104]
Hyperthyroidism ? [17,105]
Burn injuries [106,107]
Cirrhosis ? [108,109]
Starvation [110,111]
Diabetes [56,105,112]
Uremia ? [37,113]
: upregulation; ?: not determined or unclear.
× × × × ×
× × × × ×
× × × × ×
× × × ×
× × × ×
× × × × ×
× × × ×
× × × × ×
× × × × ×
× × × ×
×BMC Biochemistry 2007, 8(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/8/S1/S7
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pates in the overall activation of the UPS observed during
muscle wasting, in line with the fact that an increase in (i)
the rate of Ub conjugation to proteins, (ii) the intracellu-
lar level of ubiquitylated proteins and (iii) proteasome
activity has been described in most muscle wasting condi-
tions [6,8]; see also Table 1]. However, it should be noted
that, despite the upregulation of their corresponding
mRNA, the level of many UPS proteins does not appear
significantly altered during muscle wasting. The reasons
for this discrepancy are unclear, but an interesting hypoth-
esis is that the increased synthesis of these proteins is com-
pensated by an accelerated turnover under the conditions
analyzed.
The first specific UPS pathway described to be involved in
muscle wasting was the ‘N-end rule’ pathway ([26,27]; see
also section on Substrates of the UPS during muscle wasting),
which rapidly degrades proteins with destabilizing N-ter-
minal residues (see [28] for review). In mammals, this
pathway involves a specific E2 (E2-14K) and several E3
isoforms [29], among which E3α-II (also known as
UBR2) is increased in skeletal muscle during cachexia
[27]. The specific inhibition of this E3 reduces the rate of
ubiquitylation of soluble or model proteins in muscle
extracts from tumor-bearing or septic rats, as well as in
C2C12 cell extracts [26,27].
Transcriptome analyses showed that two other types of E3
or E3 components are upregulated in most muscle wast-
ing models. These are the F-box component MAFbx (also
known as Atrogin-1) of the SCFMAFbx E3 and the MuRF
family of RING finger E3s [30,31], which interact with
and possibly ubiquitylate a variety of myofibrillar pro-
teins [32,33]. Expression of MAFbx and MuRF-1 mRNAs
increases dramatically in catabolic states and mice defi-
cient in either of them are partially resistant to denerva-
tion atrophy [31]. Therefore, MAFbx and MuRF-1 play a
crucial role in the loss of muscle proteins and their
mRNAs are now considered to be specific atrophic mark-
ers.
Substrates of the UPS during muscle wasting
The major proteins in muscle are the myofibrillar compo-
nents; however, although monomeric actin and myosin
can be degraded by the UPS, it is assumed that this is not
the case in intact myofibers since specific interactions
between these proteins protects them from degradation
by this system [34]. Thus, an early step in muscle wasting
must be the dissociation or at least the destabilization of
the myofibrils, a process in which non-UPS proteases
shown to be involved in muscle wasting (such as calpains
[35,36], caspase 3 [37] or cathepsin L [38]) probably play
a key role. Though the early involvement of non-UPS pro-
teases in the destabilization of myofibrils has not been
formally demonstrated, this hypothesis is likely since it
helps to explain the observed role of the UPS N-end rule
pathway in muscle wasting. Indeed, this pathway requires
the substrate to expose a destabilizing N-terminal residue
[28], a feature that is rare for native cellular proteins; how-
ever, polypeptides with a destabilizing N-terminal residue
can be produced by proteolytic cleavage of native proteins
by cellular proteases [39].
Another mechanism that controls myofibril organization
involves the sarcomeric scaffold protein titin, which pos-
sesses a protein kinase domain essential for sarcomere
integrity [40,41]. Interestingly, the activity of this domain
is modulated by mechanical strain [42], allowing titin to
convert tension forces into molecular signals. This func-
tion controls both the intracellular level and localization
of the RING finger E3 MuRF-2 (a protein closely related to
MuRF-1), which is associated with titin in the sarcomeres
through interaction with the UBD (Ub binding domain
[43])-containing proteins Nbr1 and p62, and is translo-
cated to the nucleus upon muscle inactivity [44]. Nuclear
localization of MuRF-2 in turn leads to nuclear exclusion
of SRF (serum response factor) [44], a transcription factor
central to muscle response to hypertrophic stimuli. Thus,
titin appears to be an important relay in the control of
muscle disuse atrophy, since it is able to couple mechani-
cal inactivity with muscle wasting by triggering macromo-
lecular rearrangements of sarcomeres and altering muscle
transcriptional programs. The importance of the titin–
Nbr1–p62–MuRF-2 interaction is underlined by a human
mutation disrupting binding of Nbr1 to titin, which
causes an autosomal dominant muscle disease called
heredity myopathy with early respiratory failure (HMERF)
[44]. In muscle biopsies of HMERF patients, the structure
of sarcomeres is altered and the localization of Nbr1, p62
and MuRF-2 is abnormal [44].
In addition to these mechanisms, the crucial roles of
MAFbx and MuRF-1 during atrophy indicate that these
E3s target key negative regulators of muscle wasting for
degradation. However, only a few actual or potential sub-
strates have been identified for these E3s and the rele-
vance of these substrates for muscle wasting remains
unclear (see Signaling pathways involved in muscle wasting).
Signaling pathways involved in muscle wasting
Glucocorticoids are known to be important mediators of
muscle wasting in various catabolic conditions [5];
indeed, dexamethasone triggers upregulation of various
UPS components [45]. However, the underlying mecha-
nisms of glucocorticoid signaling in muscle wasting are
not yet fully understood [23].
Presently, two families of transcription factors have been
clearly identified as crucial positive mediators of muscle
wasting: the FoxO (forkhead box O) transcription factorsBMC Biochemistry 2007, 8(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/8/S1/S7
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and NFκB [9]. Of note, these factors are involved in the
control of expression of the E3s MuRF-1 and MAFbx [46-
48].
PI3K is activated by anabolic signals triggered by insulin
or IGF-1 upon binding to their receptors, which in turn
activates Akt [49] (a kinase central to muscle hypertro-
phy), as shown in transgenic mice in which an active form
of Akt can be inducibly expressed in adult skeletal muscle
[50]. Besides its function in stimulating protein synthesis
via mTOR and GSK3 [9], a crucial role for activated Akt is
to phosphorylate FoxO [46,47,51], leading to transcrip-
tional inactivation of FoxO due to its release from DNA
and 14-3-3 protein-mediated cytoplasmic sequestration
(see [52] for review), and to subsequent inhibition of
muscle wasting. In many systemic diseases, including dia-
betes, cancer and renal failure, low circulating levels of
insulin and IGF-1, or resistance to their action, contribute
to muscle wasting via inactivation of the PI3K/Akt path-
way, which leads to the subsequent dephosphorylation
and activation of FoxO [53-56]. Interestingly, it has
recently been shown that myostatin treatment can also
trigger the same effect in mice [57]. Myostatin is a TGFβ
super-family member that acts as a negative regulator of
muscle growth and is implicated in several forms of mus-
cle wasting [58]. Myostatin signaling reverses the IGF-1/
PI3K/Akt pathway by inhibiting phosphorylation of Akt,
leading to activation of FoxO and thereby activation of
E2-14K, MuRF-1 and MAFbx [57].
In many disease states, stress or inflammatory cytokines
such as tumor necrosis factor alpha (TNFα) are produced
[59]. Stimulation of their receptors activates the IKK
kinase, which in turn phosphorylates the NFκB inhibitor
IκBα, promoting its degradation by the UPS. This leads to
the release of NFκB, which migrates to the nucleus to acti-
vate its target genes [60]. Demonstration of a role for this
pathway in muscle wasting comes from many observa-
tions, including the fact that constitutive activation of IKK
in transgenic mice triggered both a decrease in total mus-
cle mass and an increase in atrophy markers, which were
reversed by expression of IκBα [48]. A further observation
supporting a role for this pathway in muscle wasting is
that direct inhibition of NFκB inhibited cachexia in a
mouse tumor model [61]. In addition, in cancer cachexia,
tumor-derived factors such as proteolysis-inducing factor
(PIF) [62,63], or elevated levels of endogenous factors
such as angiotensin I and II, are thought to contribute to
muscle atrophy through activation of the NFκB pathway.
Supporting evidence comes from the fact that these factors
induce increased expression of UPS components (protea-
some subunits, E2-14K) and stimulate protein degrada-
tion in murine C2C12 myotubes in a manner requiring
IκBα degradation and nuclear translocation of NFκB
[64,65]. Interestingly, although activation of NFκB is also
required for muscle disuse atrophy, the NFκB family
members that are activated appear distinct from those
activated by the TNFα pathway [1,66].
NFκB and FoxO are thus key players in the activation of
muscle wasting. Interestingly, their known targets include
MuRF-1 and MAFbx for FoxO [46,47], and MuRF-1 for
NFκB [48]. However, as mentioned in the section on Sub-
strates of the UPS during muscle wasting, the key substrates
of these E3s in muscle wasting are unclear. Nevertheless,
one hypothesis is that induction of MuRF-1 activity is
important for the destabilization of myofibrillar com-
plexes required for the subsequent degradation of myofi-
brillar proteins. Indeed, the interaction between MuRF-1
and titin has been shown to be important for sarcomere
stability [67]. Furthermore, in yeast two-hybrid screens,
MuRF-1 interacts with several myofibrillar proteins (titin,
nebulin, the nebulin-related protein NRAP, troponin-I,
troponin-T, myosin light chain 2, myotilin and T-cap)
[33], suggesting that this E3 can mediate their ubiquityla-
tion and degradation in muscle. MuRF-1-mediated ubiq-
uitylation and degradation, however, has only been
proven for troponin I [68] and possibly for myosin light
chain 2 [33] in cardiac tissue. The lack of clear results
regarding the role of MuRF-1 in the degradation of its
other interactors could be due to its functional redun-
dancy with MuRF-2.
The known targets of MAFbx (calcineurin A [32] and
MyoD [69])) are unlikely to be crucial for muscle wasting,
since calcineurin A does not appear to affect myofiber size
[70] and MyoD is involved in muscle cell differentiation.
The key substrates of MAFbx in muscle wasting thus
remain to be identified. Interestingly, however, TNFα/
NFκB signaling reduces both the level of MyoD mRNA
[48] and the stability of MyoD [71], and forced expression
of MAFbx inhibits the formation of myotubes in an in vitro
model of muscle differentiation [69]. Thus, the role of
MAFbx in the down-regulation of MyoD could in fact be
indirectly important for muscle wasting, since the inacti-
vation of MyoD functions necessary for the differentiation
of muscle satellite cells possibly inhibits muscle regenera-
tion.
Concluding remarks
In this brief overview, we have summarized the role of the
UPS as an essential mediator of muscle wasting. Even
though much remains to be understood before a com-
plete picture of the intricate mechanisms controlling mus-
cle atrophy can emerge, our knowledge to date already
suffices to demonstrate that the UPS is an attractive poten-
tial target for therapeutic treatments aimed at slowing
down muscle atrophy when it becomes harmful to the
organism [5]. The different levels of possible therapeuticBMC Biochemistry 2007, 8(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/8/S1/S7
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intervention are discussed in the section on Potential tar-
gets and drugs for muscle wasting therapy.
Analysis of muscle wasting: models, knockouts 
and assays
Main models of muscle wasting
Muscle wasting occurs when the overall rate of protein
proteolysis exceeds in a sustained manner that of protein
synthesis in muscle. Since a variety of physiological and
pathological conditions can influence the equilibrium
between these two processes, several animal (mostly
murine) models have been developed (see Table 1) to
analyze the mechanisms of muscle mass loss in these dif-
ferent conditions [72]. For example, cancer, sepsis and cir-
rhosis are inflammatory conditions that induce muscle
wasting through the inhibition of anabolic pathways and
the secretion of cytokines (IL1, TNFα) or catabolic factors
(PIF), while hindlimb suspension, denervation and sarco-
penia are conditions in which disuse atrophy is present. In
most models, despite variations in the extent of involve-
ment of the UPS relative to other processes (including
other proteolytic systems), activation of UPS-dependent
proteolysis transpires to be a crucial event [6]. Moreover,
as described in the section on Roles of the UPS in muscle
wasting, biochemical and molecular analyses have deter-
mined that a convergent mechanism for this activation is
the upregulation of crucial ubiquitylation pathways
involving the N-End rule E3s as well as the E3s SCFMAFbx
and MuRF-1 [73], even though the substrates of these
enzymes during muscle wasting remain unclear at
present.
Knockouts of components involved in muscle wasting
Several mouse strains deficient in components involved
in muscle wasting have been constructed and tested for
their protection against muscle atrophy (see Table 2).
Manipulation of the N-end rule pathway, by deletion of
the genes encoding either E2-14K or the E3 UBR1 [74,75],
did not significantly impair muscle wasting, probably
because of the functional redundancy between the many
components of this pathway [29] and/or because this
pathway is only responsible for the breakdown of soluble
muscle proteins. By contrast, mice in which either the
MAFbx- or MuRF-1-encoding gene has been deleted
become partially resistant to atrophy induced by denerva-
tion, highlighting the crucial role of these two E3s in the
process of muscle wasting. Finally, mice with altered con-
trol of the NFκB pathway demonstrate the key function of
this pathway in inducing muscle atrophy.
Assays for analysis of muscle wasting
In addition to the measurement of muscle mass after iso-
lation of specific muscles from model animals, protein
breakdown in incubated muscle is often quantified by the
release of tyrosine, which is neither synthesized nor
metabolized in skeletal muscle [76]. Furthermore, release
of 3-methylhistidine, a modified amino acid found in
actin and myosin that can be neither reincorporated into
protein nor metabolized, can also be measured [77,78].
Potential targets and drugs for muscle wasting 
therapy
As summarized in the section on Roles of the UPS in muscle
wasting and figure 1, there are several levels of possible
therapeutic intervention to limit muscle wasting. The first
level is to modulate the expression or activity of circulat-
ing factors that either promote muscle hypertrophy (such
as insulin or IGF-1) [79], inhibit muscle growth (such as
myostatin) [58], or induce the UPS and/or NFκB (such as
the cytokines TNFα or IL6, the secreted glycoprotein PIF,
or oxidative stress) [5]. The second level involves targeting
intracellular effectors of muscle wasting, such as the tran-
scription factor FoxO or the NFκB pathway. Finally, a
third level of possible therapeutic intervention is direct
inhibition of the UPS.
As the exploration of these different possibilities is cur-
rently underway, only partial and limited information is
presently available. To date, most compounds presently
tested on animal models or in clinic for their ability to
limit muscle wasting are commercially available chemi-
cals, and many of them have been identified through
empirical approaches aimed at treating cachexia [80].
Among those, EPA (eicosapentaenoic acid), which has
Table 2: Mouse models genetically modified for proteins involved in muscle wasting
Genetically modified mice Effect on muscle (muscle wasting condition tested) Selected references
KO MuRF-1 Partial protection against atrophy (denervation) [31]
KO Atrogin-1/MAFbx Partial protection against atrophy (denervation) [31]
KO E2-14K Non-resistant to atrophy (fasting) [74,114]
KO UBR1 Decreased muscle mass [75]
Mdx Model for Duchenne muscular dystrophy: in these mice blockade of NFκB partially 
restores muscle function
[115]
KI FoxO FoxO overexpressing mice: negative effect on skeletal muscle mass [116]
MIKK constitutively active IKK Severe atrophy resembling cachexia [48]
MISR non-degradable IκB Protection against atrophy (denervation, tumor) [48]BMC Biochemistry 2007, 8(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/8/S1/S7
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been shown to down-regulate the increase in UPS activity
seen in cachexia [81], and thalidomide, which inhibits
production of TNFα by increasing the rate of degradation
of its mRNA [82], have demonstrated a degree of efficacy
[80,83,84].
Other inhibitors of TNFα expression represent attractive
therapeutic strategies against cachexia. Although the xan-
thine derivative pentoxifylline [85] can suppress cachexia-
induced activation of the UPS in rats [86], its effects in
clinical trials have been uncertain [87]. However, another
xanthine derivative, torbafylline (HWA 448), showed
encouraging properties in a study on animal models, since
it appeared more potent in preventing muscle wasting
than pentoxifylline [88].
Several studies have analyzed the potential effect on mus-
cle wasting of beta2 agonists such as clenbuterol [89],
fenoterol [90] and formoterol [91]. These anabolic drugs
appear effective against atrophy, mostly by counteracting
activation of the UPS. Though the potential use of clen-
buterol to treat muscle wasting appears limited since it has
deleterious side effects in humans (particularly tachycar-
dia and hypokalemia [92]), formoterol is already in use in
human therapy (against chronic obstructive pulmonary
disease) and thus appears to be an interesting candidate
for human trials.
Due to the prominent role of NFκB in cachexia, drugs
inhibiting the activation of this transcription factor have
also been tested in various settings. Active molecules
include HMB (β-hydroxy-β-methylbutyrate, a leucine
metabolite) [80], ibuprofen [80] and resveratrol, the latter
of which appears to be the most promising drug candidate
for clinical use against muscle wasting [84,93].
Since the proteasome is a central component in muscle
wasting, it represents an attractive target despite its pleio-
tropic functions. Indeed, many studies in animals have
demonstrated that proteasome inhibitors are efficient at
blocking muscle wasting [6,94]; however, no report on
their effect on muscle wasting in humans has yet been
Potential therapeutic targets in muscle wasting Figure 1
Potential therapeutic targets in muscle wasting. The figure illustrates possible therapeutic targets in muscle wasting, 
including circulating factors, intracellular effectors and components of the ubiquitin proteasome system (UPS).BMC Biochemistry 2007, 8(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/8/S1/S7
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published. The recent success of Millennium Pharmaceu-
ticals with the proteasome inhibitor bortezomib (PS-341,
Velcade®) for treatment of multiple myeloma [95]
prompted many biotech or pharmaceutical companies to
develop new molecules targeting the proteasome, includ-
ing Nereus (NPI-0052), Proteolix (PR-171), Santhera and
ALSTDF. Although muscle wasting is not the primary
interest of these companies, these efforts could help to
produce new compounds with interesting anti-atrophying
properties in the future.
Finally, it is important to highlight that, when possible,
muscular exercise is an efficient method of limiting disuse
atrophy since, as shown by analyses in humans, it nega-
tively influences the signaling pathways activated in mus-
cle wasting, leading in particular to down-regulation of
the E3s MAFbx and MuRF-1 [96].
New frontiers in drug discovery
Knowledge of the molecular mechanisms responsible for
muscle wasting, as summarized in figure 1, has been
acquired relatively recently and much remains to be
understood before a more accurate description of this
process is obtained. For example, the contribution of the
AP-1 transcription factors to muscle wasting [97], or of the
p38 MAP kinase to activation of MAFbx [98], remains to
be clarified. In addition, future studies will certainly char-
acterize novel factors involved in atrophy and provide a
better evaluation of the therapeutic potential of activating
or inhibiting the many pathways controlling muscle wast-
ing. Nevertheless, as several levels of therapeutic interven-
tion have been identified and drug candidates are
currently being tested, it is most likely that efficient drugs
against muscle wasting will be soon available. However,
the many problems of bioavailability and of specific tar-
geting of muscle tissues remain to be solved in most cases.
A clear limitation in the current attempts to reduce muscle
wasting is that the targeted molecules are not muscle-spe-
cific; meaning that alteration of their expression or activity
is bound to induce side effects that could worsen the clin-
ical status of the patient. A combination of drugs display-
ing synergistic effects, as shown recently for pentoxifylline
and formoterol [55], could help to improve treatment
since this strategy could allow use of sub-therapeutic
doses of each drug, decreasing the possibility of harmful
side effects.
Clearly, an alternative goal is to develop compounds that
will target specific factors that are key for muscle wasting
and that have no general functions outside muscle. In this
respect, the E3s specifically induced during muscle wast-
ing, such as the N-end rule E3s or MuRF-1, are extremely
attractive candidates. However, as illustrated in the
Mdm2/p53 pathway (see [99] for review), the best
approach to obtain specific and efficient inhibitors of E3s
is to aim to disrupt the interaction of the E3 with its sub-
strate(s). This requires substantial information on the
nature of the relevant substrates of the E3 and on the
structure of the E3–substrate pair to be targeted. As such
information is presently not available for the E3s involved
in muscle wasting, important goals for the future are to
identify their substrates and to define the structural basis
of their interaction with these substrates.
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